MicroRNA-29a Functions As a Tumor Suppressor in Nasopharyngeal Carcinoma 5-8F Cells Through Targeting VEGF

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2019 Jun 21

PMID 31217935

Citations 4

Authors

Qingyuan Shi

Jinhua Dai

Lizhen Huang

Affiliations

Soon will be listed here.

Abstract

Objectives: microRNA-29 (miR-29) family miRNAs have been mentioned as tumor suppressive genes in several human cancers. The purpose of this study was to investigate the function of miR-29a in nasopharyngeal carcinoma (NPC) cells.

Materials And Methods: Human NPC cell line 5-8F was transfected with mimic, inhibitor or scrambled controls specific for miR-29a. Subsequently, cell viability, migration, apoptosis and expression changes of VEGF were assessed by trypan blue staining, MTT assay, transwell assay, flow cytometry, Western blot and RT-qPCR. TargetScan online database was used to predict the targets of miR-29a, and luciferase reporter assay was carried out for testing the targeting relationship between VEGF and miR-29a. Western blot analysis was performed to determine the expression changes of core proteins in PI3K/AKT and JAK/STAT pathways.

Results: Overexpression of miR-29a suppressed 5-8F cells viability and relative migration, but increased apoptotic cell rate. Consistently, Bcl-2 was downregulated, Bax was upregulated, and caspase-3 and -9 were cleaved by miR-29a overexpression. VEGF was a target gene of miR-29a. Besides, VEGF silence exerted similar effects like miR-29a, as the viability and migration were repressed and apoptosis was induced. Finally, we found that PI3K/AKT and JAK/STAT pathways were deactivated by miR-29a or VEGF silence.

Conclusion: These findings highlighted the tumor suppressive effects of miR-29a on NPC cells, as its overexpression inhibited 5-8F cells viability, migration, and induced apoptosis. miR-29a exerted tumor suppressive functions might be via targeting VEGF and deactivating PI3K/AKT and JAK/STAT pathways.

Citing Articles

Interactive role of miR-29, miR-93, miR-205, and VEGF in salivary adenoid cystic carcinoma.

Bayat P, Mahdavi N, Younespour S, Khoozestani N Clin Exp Dent Res. 2022; 9(1):112-121.

PMID: 36281584 PMC: 9932236. DOI: 10.1002/cre2.678.

Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.

Li H, Deng N, He X, Li Y Biomark Res. 2022; 10(1):52.

PMID: 35883139 PMC: 9327212. DOI: 10.1186/s40364-022-00397-x.

The interplay of cytokine signaling and non-coding RNAs in head and neck squamous cell carcinoma pathobiology.

Swati , Sharma V Mol Biol Rep. 2022; 49(11):10825-10847.

PMID: 35871482 DOI: 10.1007/s11033-022-07770-x.

LncRNA LHFPL3-AS1 contributes to tumorigenesis of melanoma stem cells via the miR-181a-5p/BCL2 pathway.

Zhang S, Wan H, Zhang X Cell Death Dis. 2020; 11(11):950.

PMID: 33149126 PMC: 7643105. DOI: 10.1038/s41419-020-03141-1.

References

Zhang F, Zhang J . Clinical hereditary characteristics in nasopharyngeal carcinoma through Ye-Liang's family cluster. Chin Med J (Engl). 2001; 112(2):185-7. View

Lee A, Sze W, Au J, Leung S, Leung T, Chua D . Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 2005; 61(4):1107-16. DOI: 10.1016/j.ijrobp.2004.07.702. View

Chang E, Adami H . The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765-77. DOI: 10.1158/1055-9965.EPI-06-0353. View

Park S, Lee J, Ha M, Nam J, Kim V . miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 2008; 16(1):23-9. DOI: 10.1038/nsmb.1533. View

Xu H, Cheung I, Guo H, Cheung N . MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009; 69(15):6275-81. PMC: 2719680. DOI: 10.1158/0008-5472.CAN-08-4517. View

Slattery M, Lundgreen A, Kadlubar S, Bondurant K, Wolff R . JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog. 2011; 52(2):155-66. PMC: 3430812. DOI: 10.1002/mc.21841. View

Luo Z, Zhang L, Li Z, Li X, Li G, Yu H . An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics. 2012; 5:3. PMC: 3293045. DOI: 10.1186/1755-8794-5-3. View

Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z . Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem. 2012; 46(1-2):49-53. DOI: 10.1016/j.clinbiochem.2012.09.002. View

Schmitt M, Philippidou D, Reinsbach S, Margue C, Wienecke-Baldacchino A, Nashan D . Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun Signal. 2012; 10(1):41. PMC: 3541122. DOI: 10.1186/1478-811X-10-41. View

10.

Chen J . Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications. World J Virol. 2013; 1(6):154-61. PMC: 3782276. DOI: 10.5501/wjv.v1.i6.154. View

11.

Chen L, Xiao H, Wang Z, Huang Y, Liu Z, Ren H . miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. BMB Rep. 2013; 47(1):39-44. PMC: 4163842. DOI: 10.5483/bmbrep.2014.47.1.079. View

12.

Wang H, Yan L, Shao Q, Fu S, Zhang Z, Ye W . Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing. Clin Chem. 2014; 60(5):773-82. DOI: 10.1373/clinchem.2013.214213. View

13.

Rossi M, Amodio N, Di Martino M, Tagliaferri P, Tassone P, Cho W . MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol. 2014; 15(5):459-67. DOI: 10.2174/1389201015666140519104743. View

14.

Hong Q, Fang J, Pang Y, Zheng J . Prognostic value of the microRNA-29 family in patients with primary osteosarcomas. Med Oncol. 2014; 31(8):37. DOI: 10.1007/s12032-014-0037-1. View

15.

Rocci A, Hofmeister C, Pichiorri F . The potential of miRNAs as biomarkers for multiple myeloma. Expert Rev Mol Diagn. 2014; 14(8):947-59. DOI: 10.1586/14737159.2014.946906. View

16.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

17.

Qiu F, Sun R, Deng N, Guo T, Cao Y, Yu Y . miR-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating SPARC and COL3A1 gene expression. PLoS One. 2015; 10(3):e0120969. PMC: 4364736. DOI: 10.1371/journal.pone.0120969. View

18.

Wang S, Chai D, Chen C, Wang Z, Wang L . HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway. Biomed Pharmacother. 2015; 75:33-9. DOI: 10.1016/j.biopha.2015.08.027. View

19.

Li R, Liu J, Li Q, Chen G, Yu X . miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3. Tumour Biol. 2015; 37(3):3987-96. DOI: 10.1007/s13277-015-4165-9. View

20.

Chen D, Feng L, Ye R, He Y, Wang Y . [miR-29b Reduces Cisplatin Resistance of Gastric Cancer Cell by Targeting PI3K/Akt Pathway]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015; 37(5):514-9. DOI: 10.3881/j.issn.1000-503X.2015.05.005. View